The tweet was deleted by the author.
But we saved everything 🙂.
Inhibrx Biosciences has announced a clinical update for its investigational therapy INBRX106 in first-line head and neck cancer.
The company revealed new information via a press release, highlighting progress in its ongoing clinical development program for patients with head and neck squamous cell carcinoma. The update underscores Inhibrx Biosciences' focus on innovative therapeutics targeting oncology and rare diseases, as INBRX106 continues to advance through early stage trials.
Inhibrx Biosciences has previously engaged with clinicians and researchers at a Colorado symposium to drive progress in sarcoma research. The company also supported Swedish Sarcoma Day, highlighting research and patient advocacy efforts. Both initiatives reflect ongoing involvement in rare disease and oncology programs.